Influenza Anti-Stalk Antibodies: Development of a New Method for the Evaluation of the Immune Responses to Universal Vaccine.

Vaccines (Basel) 2020 Jan 24;8(1). Epub 2020 Jan 24.

VisMederi Research s.r.l., 53100 Siena, Italy.

Growing interest in universal influenza vaccines and novel administration routes has led to the development of alternative serological assays that are able to detect antibodies against conserved epitopes. We present a competitive ELISA method that is able to accurately determine the ratio of serum immunoglobulin G directed against the different domains of the hemagglutinin, the head and the stalk. Human serum samples were treated with two variants of the hemagglutinin protein from the A/California/7/2009 influenza virus. The signals detected were assigned to different groups of antibodies and presented as a ratio between head and stalk domains. A subset of selected sera was also tested by hemagglutination inhibition, single radial hemolysis, microneutralization, and enzyme-linked lectin assays. Pre-vaccination samples from adults showed a quite high presence of anti-stalk antibodies, and the results were substantially in line with those of the classical serological assays. By contrast, pre-vaccination samples from children did not present anti-stalk antibodies, and the majority of the anti-hemagglutinin antibodies that were detected after vaccination were directed against the head domain. The presented approach, when supported by further assays, can be used to assess the presence of specific anti-stalk antibodies and the potential boost of broadly protective antibodies, especially in the case of novel universal influenza vaccine approaches.

Download full-text PDF

Source
http://dx.doi.org/10.3390/vaccines8010043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158664PMC
January 2020

Publication Analysis

Top Keywords

anti-stalk antibodies
16
serological assays
8
pre-vaccination samples
8
universal influenza
8
head stalk
8
antibodies
8
presented approach
4
groups antibodies
4
assigned groups
4
detected assigned
4
signals detected
4
influenza
4
antibodies presented
4
presented ratio
4
domain presented
4
subset selected
4
domains subset
4
stalk domains
4
ratio head
4
virus signals
4

Similar Publications

Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for Protection in a Serum Transfer Mouse Challenge Model.

mBio 2017 09 19;8(5). Epub 2017 Sep 19.

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

The immunogenicity of current influenza virus vaccines is assessed by measuring an increase of influenza virus-specific antibodies in a hemagglutination inhibition assay. This method exclusively measures antibodies against the hemagglutinin head domain. While this domain is immunodominant, it has been shown that hemagglutination inhibition titers do not always accurately predict protection from disease. Read More

View Article and Full-Text PDF
September 2017

Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.

J Virol 2014 Nov 10;88(22):13260-8. Epub 2014 Sep 10.

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Unlabelled: Influenza virus infections are a major public health concern and cause significant morbidity and mortality worldwide. Current vaccines are effective but strain specific due to their focus on the immunodominant globular head domain of the hemagglutinin (HA). It has been hypothesized that sequential exposure of humans to hemagglutinins with divergent globular head domains but conserved stalk domains could refocus the immune response to broadly neutralizing epitopes in the stalk. Read More

View Article and Full-Text PDF
November 2014

Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans.

mSphere 2017 Nov-Dec;2(6). Epub 2017 Dec 13.

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Human influenza virus infections with avian subtype H7N9 viruses are a major public health concern and have encouraged the development of effective H7 prepandemic vaccines. In this study, baseline and postvaccination serum samples of individuals aged 18 years and older who received a recombinant H7 hemagglutinin vaccine with and without an oil-in-water emulsion (SE) adjuvant were analyzed using a panel of serological assays. While only a small proportion of individuals seroconverted to H7N9 as measured by the conventional hemagglutination inhibition assay, our data show strong induction of anti-H7 hemagglutinin antibodies as measured by an enzyme-linked immunosorbent assay (ELISA). Read More

View Article and Full-Text PDF
December 2017

Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus.

mBio 2018 01 23;9(1). Epub 2018 Jan 23.

Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

Influenza virus hemagglutinin (HA) surface glycoprotein is currently the primary target of licensed influenza vaccines. Recently, broadly reactive antibodies that target the stalk region of the HA have become a major focus of current novel vaccine development. These antibodies have been observed in humans after natural infection with influenza A virus, but the data are limited. Read More

View Article and Full-Text PDF
January 2018